The linked FDA records identify The General Hospital Corporation, d/b/a Massachusetts as the applicant on one 510(k) premarket notification, K260063, for a device named GSPE Spacer. The submission was received January 8, 2026 and decided September 11, 2026 with decision code SESE, described as Substantially Equivalent. The clearance letter lists the device under 21 CFR 888.3560, the regulation for a knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis, in Class II with product code JWH. [1][2][5]
The documented device and its regulatory classification
K260063 covers the GSPE Spacer, classified as a Class II orthopedic device under product code JWH and regulation 21 CFR 888.3560. The FDA clearance letter names the regulation as Knee Joint Patellofemorotibial Polymer/Metal/Polymer Semi-Constrained Cemented Prosthesis and lists product codes JWH and MBB. The openFDA record associates the submission with the device name Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer and an orthopedic medical specialty. [1][2]
The clearance letter states that, considering indications for use, design, principles of operation, materials and performance characteristics, the GSPE Spacer is substantially equivalent to the identified predicate and reference devices. The submission is recorded as a Traditional 510(k) with a Summary rather than a statement, and the third-party review flag is marked N. [1][2]
Submission timeline and review record
The FDA record gives a date received of January 8, 2026 and a decision date of September 11, 2026. One third-party database reports the interval as a 246-day FDA review, a figure that appears only in that source and is not stated in the FDA clearance letter. The clearance letter is dated September 11, 2026 and carries a document control number. [1][2][8]
The applicant's address in the FDA record is listed as General Hospital, MGB Innovation Suite 999, 399 Revolution Dr., Somerville, MA 02145, with contact Orhun Muratoglu. The clearance letter is addressed to the applicant care of Hollace Rhodes, Vice President, Orthopedic Regulatory Affairs, MCRA, LLC, 803 7th St., NW, Washington, District of Columbia 20001. These are filing correspondents, not verified corporate headquarters. [1][2]
Applicant identity and what the filings do not establish
The legal applicant named across the FDA record, clearance letter and third-party indexes is The General Hospital Corporation, d/b/a Massachusetts. The public documents do not verify a parent organization, brand relationship, ownership structure, website or commercial customers for this applicant, and none should be inferred from the filing address or the regulatory agent. [1][2][4][5]
The supplied collection contains one linked record, a 510(k) under product code JWH with decision SESE, and the sample of records shows the same single entry. These counts describe the supplied filings as of the snapshot date; they are not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1][5]
How the records describe the device's scope
Third-party summaries describe the GSPE Spacer as a therapeutic orthopedic device and reference gentamicin as the antibiotic considered where it matches the susceptibility pattern of the infecting microorganism. Those statements appear in secondary indexes rather than the FDA clearance letter itself, and the public documents do not provide independent performance data or clinical results for the device. [4][6]
The Innolitics record notes that, because of inherent mechanical limitations of the device materials, the device is only indicated in certain circumstances, but the supplied excerpt does not complete that indication text. The full indications for use are therefore unknown from these sources and are not restated here. [6]

